Optibrium Expands Operations in North America for AI and Computational Drug Discovery Technologies

CAMBRIDGE, England & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Optibrium, a leading developer of artificial intelligence (AI) software and solutions for drug discovery, today announced the opening of its U.S. subsidiary, Optibrium Inc., and the promotion of the Dr. Tamsin Mansley as President of the new subsidiary to lead its US-based business team and operations. Opening Strengthens Company’s Direct Sales, Technical and Application Support for New and Existing U.S. Customers, Expanding Global Presence and Customer Base of StarDrop™ and Optibrium’s Augmented Chemistry® platforms.

Based in Cambridge, MA, Optibrium Inc. is part of a vibrant network of life science biotechnology and pharmaceutical companies. The headcount of Optibrium’s US-based team doubled in 2022, and the opening of Optibrium Inc. will further enable this rapid growth trajectory and create additional recruiting opportunities, including including business development and application scientist roles.

Tamsin joined Optibrium in 2015 as Head of North American Operations, before also being named Global Head of Application Science in 2021. During her time at Optibrium, Tamsin significantly grew her US-based team. United, its customer base and its operational capacity. She has over 16 years of experience in the development and commercialization of computational modeling and chemoinformatics software, with previous roles at other key companies in the field including OpenEye, Dotmatics and Certara. Working on research and discovery programs at UCB Research and Eli Lilly, Tamsin has developed extensive expertise in medicinal chemistry. She holds a PhD in Organic Chemistry from the University of East Anglia, a BSc in Chemistry, Life Systems and Pharmaceuticals from the University of York and did postdoctoral research at the University of Texas .

Dr. Tamsin Mansley, President of Optibrium Inc., said:I am delighted to see our growth celebrated with the opening of Optibrium Inc. – a true reflection of the excellent work of our American team. The opening is an exciting development that gives Optibrium a stronger position in the global drug discovery market and allows us to better support our US-based customers in the field..”

Dr. Matthew Segall, CEO of Optibrium, commented:The creation of Optibrium Inc. is a significant milestone that demonstrates our trajectory towards future growth and is a testament to the hard work and commitment of Tamsin and his team. It strengthens the global position of our innovative AI platforms and in silico technologies, and I am confident that Optibrium Inc. will accelerate the next phase of our development..”

For more information on Optibrium, StarDrop or Cerella, please visit www.optibrium.com, contact [email protected] or call +44 1223 815900.

About Armand Downs

Check Also

Week in Review: Insilico Signs Six AI-Drug Discovery Deal with Sanofi Worth Up to $1.2 Billion

jittawit.21 Offers and financing Insilico Medicine, a Hong Kong and New York-based AI drug discovery …